Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secretion from the perfused rat pancreas
- PMID: 744105
- DOI: 10.1210/endo-103-2-610
Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secretion from the perfused rat pancreas
Abstract
Gastric inhibitory polypeptide (GIP) produced an increase in immunoreactive insulin (IRI) and immunoreactive glucagon (IRG) release from the isolated perfused rat pancreas. The magnitude of both effects was shown to be dependent on the prevailing glucose concentration. GIP stimulated IRG release at glucose concentrations less than 5.5 mM and IRI release at glucose levels greater than 5.5 mM. Arginine"stimulated IRG secretion in the presence of low glucose (2.7 mM) was potentiated by GIP. In contrast, GIP augmented arginine-stimulated insulin release only in the presence of arginine concentrations of (less than 20 mM, producing no further increase over a maximal arginine stimulus. The glucagonotropic effect of GIP in the presence of arginine was found to be suppressed by glucose, with the opposite effect observed with insulin release. It was concluded that the endocrine pancreatic action of GIP depends to a great degree on existing levels of modulating nutrients in the blood.
Similar articles
-
The interaction of vasoactive intestinal polypeptide (VIP), glucose and arginine on the secretion of insulin, glucagon and somatostatin in the perfused rat pancreas.Diabetologia. 1980 Aug;19(2):137-42. doi: 10.1007/BF00421860. Diabetologia. 1980. PMID: 6106616
-
The insulinotropic action of gastric inhibitory polypeptide in the perfused isolated rat pancreas.Endocrinology. 1976 Sep;99(3):780-5. doi: 10.1210/endo-99-3-780. Endocrinology. 1976. PMID: 954669
-
Effects of cholecystokinin, gastric inhibitory polypeptide, and secretin on insulin and glucagon secretion in rats.Endocrinology. 1982 Apr;110(4):1268-72. doi: 10.1210/endo-110-4-1268. Endocrinology. 1982. PMID: 7037370
-
GIP and the entero-insular axis.Clin Endocrinol Metab. 1979 Jul;8(2):365-77. doi: 10.1016/s0300-595x(79)80047-x. Clin Endocrinol Metab. 1979. PMID: 383323 Review. No abstract available.
-
Gastric inhibitory polypeptide.Clin Gastroenterol. 1980 Sep;9(3):679-98. Clin Gastroenterol. 1980. PMID: 6107191 Review.
Cited by
-
Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes.Diabetes. 2009 Jun;58(6):1342-9. doi: 10.2337/db08-0958. Epub 2009 Mar 10. Diabetes. 2009. PMID: 19276444 Free PMC article. Clinical Trial.
-
The past, present, and future physiology and pharmacology of glucagon.Cell Metab. 2022 Nov 1;34(11):1654-1674. doi: 10.1016/j.cmet.2022.10.001. Cell Metab. 2022. PMID: 36323234 Free PMC article. Review.
-
The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class?J Diabetes Res. 2015;2015:806979. doi: 10.1155/2015/806979. Epub 2015 May 17. J Diabetes Res. 2015. PMID: 26075286 Free PMC article. Review.
-
Exploring the molecular mechanisms underlying α- and β-cell dysfunction in diabetes.Diabetol Int. 2017 Jun 29;8(3):248-256. doi: 10.1007/s13340-017-0327-x. eCollection 2017 Aug. Diabetol Int. 2017. PMID: 30603330 Free PMC article.
-
GIP and GLP-1, the two incretin hormones: Similarities and differences.J Diabetes Investig. 2010 Apr 22;1(1-2):8-23. doi: 10.1111/j.2040-1124.2010.00022.x. J Diabetes Investig. 2010. PMID: 24843404 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources